Dr John Newcomer reviews the Schizophrenia pipeline

Reviewing the schizophrenia drug pipeline for the inThought Expert Discussion Series, Dr. John Newcomer does not see efficacy data that substantially differentiates new agents from currently approved drugs. Dr. John Newcomer is the Gregory B. Couch Professor of Psychiatry at the Washington University School of Medicine. He is also Director of the Clinical Trials Unit at the Institute of Clinical and Translational Sciences (ICTS).